TA-65 Pharmacokinetic Study

A Pharmacokinetic And Relative Bioavailability Of Different Formulation Of Nutritional Supplement TA-65 In Healthy Volunteers: A Pilot, Replicate Cross-Over Study

This study is a pilot research study in humans to determine the steady state pharmacokinetic profile of TA-65 after oral dose of formulated and unformulated forms. There will be eight (8) subjects of healthy men and women (non-child bearing). TA-65 is supposed to supplement the diet to increase general health through telomerase activation.The active ingredient in TA-65 activates an enzyme called telomerase. However, the active ingredient has poor oral bioavailability in humans. This study is created to enhance the bioavailability in telomerase with different formulations; powder and capsule form.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Dietary supplement: Dose A: TA-65 24mg, powder; Dietary supplement: Dose B: TA-65, 8mg, powder; Dietary supplement: Dose C: TA-65 3.2mg, capsule; Dietary supplement: Dose D: TA-65 8mg, capsule; Dietary supplement: Dose E: TA-65 32mg, capsule

Detailed Description

This is an open labeled, replicate cross-over study with eight (8) subjects which will include men and women (non childbearing age) and be completed over a period of six (6) weeks. The supplement TA-65 will be given to subjects in both capsules and powder form.

TA-65 is a dietary supplement. The active ingredient is isolated from roots of Astragalus species. The active ingredient has been proven to activate an enzyme called telomerase. TA-65 in intended to supplement the diet to increase the general health through telomerase activation. The active ingredient has poor oral bioavailability in humans. The current study is aimed at assessing the bioavailability of the active ingredient with different formulations designed to enhance the bioavailability.

The objective of the study is to determine the steady state pharmacokinetic profile of TA-65 following oral dose of formulated (powder and capsules) and unformulated (powder) forms as assessed by Cmax, Tmax and AUC (area under the curve).

This will be a pilot, open-label, replicate cross-over study to evaluate the pharmacokinetic profile of active ingredient in eight subjects following the oral intake of TA-65 varying in formulations and doses. The subjects are expected to participate in this study for a period of 28 days. After initial screening, all subjects will visit the study center on five different days (day 1, day 7, day 14, day 21 and day 28). During each visit, all eight subjects will orally take one of the five test materials.

The washout period is seven days during which all subjects refrain from taking TA-65 in any form.

Pharmacokinetic sampling for measurement of plasma concentrations will be conducted over a 12 hour period following the oral dose. Blood will be withdrawn from all subjects prior to the intake of the test materials (0 hr.) and 1, 2, 3, 4, 5, 7, 10 and 12 hours following the oral intake of the test material. Serum will be separated from each blood sample and stored at -20° C. The amount of TA-65 in each serum samples will be analyzed by mass spectrometry.

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10016
      • NYU Langone Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 51 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy adult male or non-childbearing potential females, 22-55 years of age
• Subjects who have signed a written informed consent consistent.
• BMI ≥ 18.5 and ≤ 32.0 at screening with a maximum weight of 120 kg
• Medically healthy and good health as deemed by PI
• Subjects who are not on any medication or dietary supplement.
• Subjects who are able to follow the protocol as designed by TA Science and NYU

Exclusion Criteria:

• History of serious medical condition or psychiatric condition
• Subject is mentally or legally incapacitated or has significant emotional problems at the time of screening visit
• Recent history of myocardial infarction.
• Subjects with a history of cancer within the last 5 years.
• Subjects currently taking any prescribed medications or any OTC (over-the-counter) dietary supplements.
• History of drug or alcohol addiction.
• Females who are pregnant, lactating, or nursing or who may become pregnant during the course of the study.
• Patients diagnosed as HIV-positive, diagnosed with AIDS.
• Clinically significant infection within 3 months prior to screening as determined by the PI
• Consumption of grapefruit or grapefruit juice within seven days prior to the first dose of study medication and throughout the pharmacokinetic phase of the study.
• Patients with any condition not previously named that, in the opinion of the investigators or intake staff, would jeopardize the safety of the patient or affect the validity of the data collected in this study.
• Has donated blood within 3 months of screening visit or plans to donate blood within 3 months of study completion.
• Plasma donation within 7 days prior to dosing of test product
• Participation in another clinical trial within 30 days prior to screening.
• Allergy to heparin

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dose A, B, C, D, E; All participants will receive all doses throughout the course of the study.	Dietary supplement: Dose A: TA-65 24mg, powder; Other Names: CAG; Dietary supplement: Dose B: TA-65, 8mg, powder; Dietary supplement: Dose C: TA-65 3.2mg, capsule; Dietary supplement: Dose D: TA-65 8mg, capsule; Dietary supplement: Dose E: TA-65 32mg, capsule
Experimental: Dose D, E, C, B, A; All participants will receive all doses throughout the course of the study.	Dietary supplement: Dose A: TA-65 24mg, powder; Other Names: CAG; Dietary supplement: Dose B: TA-65, 8mg, powder; Dietary supplement: Dose C: TA-65 3.2mg, capsule; Dietary supplement: Dose D: TA-65 8mg, capsule; Dietary supplement: Dose E: TA-65 32mg, capsule
Experimental: Dose C, D, E, A, B; All participants will receive all doses throughout the course of the study.	Dietary supplement: Dose A: TA-65 24mg, powder; Other Names: CAG; Dietary supplement: Dose B: TA-65, 8mg, powder; Dietary supplement: Dose C: TA-65 3.2mg, capsule; Dietary supplement: Dose D: TA-65 8mg, capsule; Dietary supplement: Dose E: TA-65 32mg, capsule
Experimental: Dose E, D, C, B, A; All participants will receive all doses throughout the course of the study.	Dietary supplement: Dose A: TA-65 24mg, powder; Other Names: CAG; Dietary supplement: Dose B: TA-65, 8mg, powder; Dietary supplement: Dose C: TA-65 3.2mg, capsule; Dietary supplement: Dose D: TA-65 8mg, capsule; Dietary supplement: Dose E: TA-65 32mg, capsule

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Concentration (c max) of TA-65 in serum		12 hours
Time to reach maximum concentration (T max) of TA-65 in serum		12 hours
Area Under the Curve (AUC)	For a given time interval (t2-t1), the AUC is calculated as follows: AUC =1/2 (C1+C2)(t2-t1) Where the C1 and C2 are the amount of the test product in blood at time 1 (t1) and time 2 (t2) respectively. Average concentration of test material in the body over the total time interval will be calculate by the sum of all of the intervals together from the first time point to the last.	12 hours

Collaborators and Investigators

• Sponsor: NYU Langone Health
• Investigators: Principal Investigator: David Keefe, MD, NYU Langone Medical Center

Study record dates

Study Major Dates

• Study Start: September 1, 2016
• Primary Completion (Actual): November 1, 2016
• Study Completion (Actual): February 1, 2017

Study Registration Dates

• First Submitted: April 4, 2016
• First Submitted That Met QC Criteria: April 7, 2016
• First Posted (Estimate): April 8, 2016

Study Record Updates

• Last Update Posted (Actual): May 9, 2018
• Last Update Submitted That Met QC Criteria: May 8, 2018
• Last Verified: May 1, 2018

More Information

Terms related to this study

• Keywords: Dietary Supplement; TA-65; Telemorase
• Other Study ID Numbers: 15-00834

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No